Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents (2016 - 2026)

Veracyte's Cash & Equivalents history spans 14 years, with the latest figure at $362.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 51.65% to $362.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $362.6 million, a 51.65% increase, with the full-year FY2025 number at $362.6 million, up 51.65% from a year prior.
  • Cash & Equivalents hit $362.6 million in Q4 2025 for Veracyte, up from $315.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VCYT hit a ceiling of $362.6 million in Q4 2025 and a floor of $153.4 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $223.0 million across 5 years, with a median of $205.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 122.14% in 2021 and later crashed 53.15% in 2022.
  • Tracing VCYT's Cash & Equivalents over 5 years: stood at $173.2 million in 2021, then dropped by 10.94% to $154.2 million in 2022, then skyrocketed by 40.33% to $216.5 million in 2023, then increased by 10.46% to $239.1 million in 2024, then skyrocketed by 51.65% to $362.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for VCYT at $362.6 million in Q4 2025, $315.6 million in Q3 2025, and $219.5 million in Q2 2025.